The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a survei...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/10/2661 |
| _version_ | 1797574632670232576 |
|---|---|
| author | Eleonora Nicolai Flaminia Tomassetti Martina Pelagalli Serena Sarubbi Marilena Minieri Alberto Nisini Marzia Nuccetelli Marco Ciotti Massimo Pieri Sergio Bernardini |
| author_facet | Eleonora Nicolai Flaminia Tomassetti Martina Pelagalli Serena Sarubbi Marilena Minieri Alberto Nisini Marzia Nuccetelli Marco Ciotti Massimo Pieri Sergio Bernardini |
| author_sort | Eleonora Nicolai |
| collection | DOAJ |
| description | The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection. |
| first_indexed | 2024-03-10T21:26:02Z |
| format | Article |
| id | doaj.art-fe9d933699454402b494d17e6df4b67c |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T21:26:02Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-fe9d933699454402b494d17e6df4b67c2023-11-19T15:45:16ZengMDPI AGBiomedicines2227-90592023-09-011110266110.3390/biomedicines11102661The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow UpEleonora Nicolai0Flaminia Tomassetti1Martina Pelagalli2Serena Sarubbi3Marilena Minieri4Alberto Nisini5Marzia Nuccetelli6Marco Ciotti7Massimo Pieri8Sergio Bernardini9Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Diagnostic Imaging and Radiology, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, ItalyDepartment of Laboratory Medicine, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, ItalyDepartment of Laboratory Medicine, Virology Unit, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyThe use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection.https://www.mdpi.com/2227-9059/11/10/2661SARS-CoV-2antibodiesserological testvaccine |
| spellingShingle | Eleonora Nicolai Flaminia Tomassetti Martina Pelagalli Serena Sarubbi Marilena Minieri Alberto Nisini Marzia Nuccetelli Marco Ciotti Massimo Pieri Sergio Bernardini The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up Biomedicines SARS-CoV-2 antibodies serological test vaccine |
| title | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
| title_full | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
| title_fullStr | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
| title_full_unstemmed | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
| title_short | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
| title_sort | antibodies response to sars cov 2 vaccination 1 year follow up |
| topic | SARS-CoV-2 antibodies serological test vaccine |
| url | https://www.mdpi.com/2227-9059/11/10/2661 |
| work_keys_str_mv | AT eleonoranicolai theantibodiesresponsetosarscov2vaccination1yearfollowup AT flaminiatomassetti theantibodiesresponsetosarscov2vaccination1yearfollowup AT martinapelagalli theantibodiesresponsetosarscov2vaccination1yearfollowup AT serenasarubbi theantibodiesresponsetosarscov2vaccination1yearfollowup AT marilenaminieri theantibodiesresponsetosarscov2vaccination1yearfollowup AT albertonisini theantibodiesresponsetosarscov2vaccination1yearfollowup AT marzianuccetelli theantibodiesresponsetosarscov2vaccination1yearfollowup AT marcociotti theantibodiesresponsetosarscov2vaccination1yearfollowup AT massimopieri theantibodiesresponsetosarscov2vaccination1yearfollowup AT sergiobernardini theantibodiesresponsetosarscov2vaccination1yearfollowup AT eleonoranicolai antibodiesresponsetosarscov2vaccination1yearfollowup AT flaminiatomassetti antibodiesresponsetosarscov2vaccination1yearfollowup AT martinapelagalli antibodiesresponsetosarscov2vaccination1yearfollowup AT serenasarubbi antibodiesresponsetosarscov2vaccination1yearfollowup AT marilenaminieri antibodiesresponsetosarscov2vaccination1yearfollowup AT albertonisini antibodiesresponsetosarscov2vaccination1yearfollowup AT marzianuccetelli antibodiesresponsetosarscov2vaccination1yearfollowup AT marcociotti antibodiesresponsetosarscov2vaccination1yearfollowup AT massimopieri antibodiesresponsetosarscov2vaccination1yearfollowup AT sergiobernardini antibodiesresponsetosarscov2vaccination1yearfollowup |